462651-80-5

Basic information

• Product Name: Imidazo[1,2-a]pyrimidin-7-amine (9CI)
• Synonyms: Imidazo[1,2-a]pyrimidin-7-amine (9CI);7-Aminoimidazo[1,2-a]pyrimidine;iMidazo[1,2-a]pyriMidin-7-aMine
• CAS NO: 462651-80-5
• Molecular Formula: C₆H₆N₄
• Molecular Weight: 134.13864
• Product Categories: AMINETERTIARY;organic building block
• Mol File: 462651-80-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.5 g/cm³
• Refractive Index: 1.773
• CAS DataBase Reference: Imidazo[1,2-a]pyrimidin-7-amine (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyrimidin-7-amine (9CI)(462651-80-5)
• EPA Substance Registry System: Imidazo[1,2-a]pyrimidin-7-amine (9CI)(462651-80-5)

Safety Data

• Hazardous Substances Data: 462651-80-5(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyrimidin-7-amine, also known by the CAS Number 140947-58-7, is a compound categorized under the class of Imidazopyrimidines, which are polycyclic aromatic compounds containing an imidazole ring fused to a pyrimidine ring. There isn't widespread information about its uses, but substances under this class are typically used in medical and biochemical research due to their diversity of chemical and biological activities. The compound is typically sold in solid form, and we currently lack data about its specific physical and chemical properties including solubility, melting point, boiling point and toxicity. It's always recommended to handle this compound with care and carry out necessary safety measures until more about its properties and potential hazards is understood.

InChI:InChI=1/C6H6N4/c7-5-1-3-10-4-2-8-6(10)9-5/h1-4H,(H2,7,8,9)

Upstream product

• 79-06-1 2-propenamide 
• 107-20-0 2-chloroethanal 
• 156-81-0 2,4-diaminopyrimidine 

Relevant articles and documents

REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES

A method of regio-selectively synthesizing an imidazo-pyrimidine compound of formulae (XXa) or (XXb) comprising a step of coupling a first compound of formula XX-P1a or XX-P1b with a second compound of formula XX-P2. This annulation reaction between β-ethoxy acrylamides and phosphorylated aminoimidazoles to furnish imidazo[1,2-a]pyrimidin-amines relies on steering effects from endocyclic and exocyclic phosphorylated aminoimidazoles. The reaction furnishes either 2-amino or 4-amino constitutional isomers of imidazo[1,2-a]pyrimidines with good yields and ranges of 90:10 – 99:1 regio-selectivity. The reaction is useful in the synthesis of various tracer molecules used in the study of neurological conditions such as where R3 and R4 together with the imidazole ring atoms to which they are bonded form a phenyl ring and the products are substituted benzimidazopyrimidines. The reaction can be generalized to form imidazo[1,2-a]pyrimidines substituted at either of their 2- and 4- positions by alkoxy or thioalkyl groups.

Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure-mutagenicity relationships for arylamine metabolites

The structure-activity relationships for a series of heteroaryl urea inhibitors of fatty acid amide hydrolase (FAAH) are described. Members of this class of inhibitors have been shown to inactivate FAAH by covalent modification of an active site serine with subsequent release of an aromatic amine from the urea electrophile. Systematic Ames II testing guided the optimization of urea substituents by defining the structure-mutagenicity relationships for the released aromatic amine metabolites. Potent FAAH inhibitors were identified having heteroaryl amine leaving groups that were non-mutagenic in the Ames II assay.

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).